MY133423A - Pharmaceutical combinations and their use in treating gastrointestinal disorders - Google Patents

Pharmaceutical combinations and their use in treating gastrointestinal disorders

Info

Publication number
MY133423A
MY133423A MYPI20005769A MYPI20005769A MY133423A MY 133423 A MY133423 A MY 133423A MY PI20005769 A MYPI20005769 A MY PI20005769A MY PI20005769 A MYPI20005769 A MY PI20005769A MY 133423 A MY133423 A MY 133423A
Authority
MY
Malaysia
Prior art keywords
gastrointestinal disorders
pharmaceutical combinations
treating gastrointestinal
combination
agent
Prior art date
Application number
MYPI20005769A
Other languages
English (en)
Inventor
Pfannkuche Hans-Jurgen
Anthony Billstein Stephen
Dumovic Peter
Franco Nicola
Thomas Iwicki Mark
Joseph Wilusz Edward Jr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY133423A publication Critical patent/MY133423A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20005769A 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders MY133423A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
MY133423A true MY133423A (en) 2007-11-30

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20005769A MY133423A (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Country Status (30)

Country Link
EP (3) EP1286668B1 (https=)
JP (1) JP2003523324A (https=)
KR (1) KR100765579B1 (https=)
CN (2) CN1875966A (https=)
AR (1) AR026916A1 (https=)
AT (1) ATE293971T1 (https=)
AU (2) AU778869B2 (https=)
BR (1) BR0016275A (https=)
CA (1) CA2388959A1 (https=)
CO (1) CO5261535A1 (https=)
CZ (1) CZ300690B6 (https=)
DE (1) DE60019814T2 (https=)
DK (1) DK1286668T3 (https=)
ES (1) ES2240229T3 (https=)
HU (1) HUP0301122A3 (https=)
IL (2) IL149496A0 (https=)
MX (1) MXPA02005695A (https=)
MY (1) MY133423A (https=)
NO (1) NO20022680L (https=)
NZ (2) NZ531489A (https=)
PE (1) PE20011030A1 (https=)
PL (1) PL202201B1 (https=)
PT (1) PT1286668E (https=)
RU (1) RU2264215C2 (https=)
SG (1) SG152025A1 (https=)
SK (1) SK8062002A3 (https=)
TR (1) TR200402293T2 (https=)
TW (1) TWI263496B (https=)
WO (1) WO2001041748A2 (https=)
ZA (1) ZA200204493B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261606A1 (en) * 2000-05-18 2001-11-26 Glaxo Group Limited Method for treating functional dyspepsia
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
JP2006528231A (ja) * 2003-05-27 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
RU2007105346A (ru) * 2004-07-14 2008-09-27 Новартис АГ (CH) Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы
MX2007009136A (es) * 2005-01-31 2007-09-06 Novartis Ag Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones.
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
RU2008152196A (ru) * 2006-06-15 2010-07-20 Новартис АГ (CH) Композиции, включающие тегасерод в отдельности или в комбинации с ингибитором протонного насоса, для лечения или профилактики повреждений желудочно-кишечного тракта
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
EP0617620B1 (en) * 1991-12-21 1998-09-09 Smithkline Beecham Plc Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
DK0794184T3 (da) * 1994-11-21 2001-07-30 Dainippon Pharmaceutical Co 6-Methoxy-1H-benzotriazol-5-carboxamidderivater, fremgangsmåde til fremstilling deraf og lægemidler indeholdende dem
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
SG152025A1 (en) 2009-05-29
AU2005200797A1 (en) 2005-03-17
AU2672801A (en) 2001-06-18
TWI263496B (en) 2006-10-11
HUP0301122A2 (hu) 2003-08-28
NZ566800A (en) 2009-11-27
HUP0301122A3 (en) 2005-03-29
CN1409634A (zh) 2003-04-09
CZ20021967A3 (cs) 2002-08-14
TR200402293T2 (tr) 2004-10-21
CN1875966A (zh) 2006-12-13
MXPA02005695A (es) 2002-09-18
NO20022680L (no) 2002-08-12
NZ531489A (en) 2005-09-30
PE20011030A1 (es) 2001-10-31
SK8062002A3 (en) 2003-04-01
PL202201B1 (pl) 2009-06-30
KR100765579B1 (ko) 2007-10-09
PL355663A1 (en) 2004-05-04
DE60019814D1 (de) 2005-06-02
EP1488788A1 (en) 2004-12-22
CA2388959A1 (en) 2001-06-14
CO5261535A1 (es) 2003-03-31
EP1286668B1 (en) 2005-04-27
DK1286668T3 (da) 2005-08-15
RU2264215C2 (ru) 2005-11-20
ATE293971T1 (de) 2005-05-15
WO2001041748A2 (en) 2001-06-14
IL149496A0 (en) 2002-11-10
JP2003523324A (ja) 2003-08-05
AR026916A1 (es) 2003-03-05
WO2001041748A3 (en) 2002-12-19
NO20022680D0 (no) 2002-06-06
BR0016275A (pt) 2002-08-27
CN1310644C (zh) 2007-04-18
KR20030016208A (ko) 2003-02-26
RU2002118316A (ru) 2004-02-20
ZA200204493B (en) 2003-09-29
ES2240229T3 (es) 2005-10-16
AU778869B2 (en) 2004-12-23
IL149496A (en) 2009-12-24
PT1286668E (pt) 2005-08-31
AU2005200797B2 (en) 2008-01-24
EP1286668A2 (en) 2003-03-05
DE60019814T2 (de) 2006-03-02
CZ300690B6 (cs) 2009-07-15
EP1913944A1 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
CY2166B1 (en) Freeze-dried composition containing ondansetron
HUP0001089A2 (hu) Gyógyászati készítmények férfiak erekciós zavarainak kezelésére
IL116083A (en) Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
IS4407A (is) Notkun samsetningarafurðar sem inniheldur samkeppnishæf prógesterónmótlyf og gestagen til framleiðslu á læknislyfi til meðhöndlunar á legslímuvillu eða bandvefsvöðvahnútum í legi
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
MY129314A (en) Pharmaceutical composition comprising sumatriptan
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
ECSP003820A (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales